Our previous study suggested that serum BDNF may be an inappropriate biomarker for deficit schizophrenia (DS), but higher serum glial cell line-derived neurotrophic factor (GDNF) levels were associated with better cognitive performance in DS patients [7]. The gene discussed is BDNF; the disease is Dravet syndrome.